Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock: Insider Michael Megna Sells 11,280 Shares

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CAO Michael Megna sold 11,280 shares of Kiniksa Pharmaceuticals International stock in a transaction on Monday, November 9th. The stock was sold at an average price of $98.54, for a total transaction of $1,111,531.20. Following the completion of the transaction, the chief accounting officer directly owned 12,697 shares in the company, valued at $1,251,162.38. This represents a 47.05% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Trading Up 0.1%

Shares of KNSA stock opened at $96.33 on Friday. Kiniksa Pharmaceuticals International, plc has a 12-month low of $37.02 and a 12-month high of $99.31. The business’s fifty day simple moving average is $82.18 and its 200-day simple moving average is $62.70. The company has a market cap of $7.57 billion, a PE ratio of 74.10 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, October 27th. The company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. The firm had revenue of $285.97 million during the quarter, compared to analysts’ expectations of $260.66 million. On average, equities analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Citigroup increased their price target on Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. boosted their price target on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Wedbush boosted their price target on Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 28th. Zacks Research downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 30th. Finally, The Goldman Sachs Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the company a “buy” rating in a research report on Wednesday, October 28th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $100.57.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

Institutional investors and hedge funds have recently made changes to their positions in the stock. Allworth Financial LP boosted its holdings in Kiniksa Pharmaceuticals International by 42.0% in the second quarter. Allworth Financial LP now owns 453 shares of the company’s stock valued at $29,000 after purchasing an additional 134 shares during the last quarter. Arizona State Retirement System grew its position in Kiniksa Pharmaceuticals International by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 10,132 shares of the company’s stock worth $648,000 after purchasing an additional 209 shares during the period. GAMMA Investing LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 21.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,278 shares of the company’s stock valued at $95,000 after buying an additional 223 shares during the last quarter. Commonwealth Equity Services LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 10,871 shares of the company’s stock valued at $811,000 after buying an additional 237 shares during the last quarter. Finally, First Trust Advisors LP raised its stake in shares of Kiniksa Pharmaceuticals International by 3.1% during the 1st quarter. First Trust Advisors LP now owns 9,876 shares of the company’s stock valued at $476,000 after buying an additional 293 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally. Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.